Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.80 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | DHODH | Q02127 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408528 | 1.00 | PDE5A (0.80) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL290253 | 0.89 | PDE5A (0.64) | PDE5AALDH1A1HPGD | |
| SCHEMBL290735 | 0.87 | PDE5A (0.78) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL6068556 | 0.85 | PDE5A (0.66) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL292190 | 0.84 | PDE5A (0.76) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29831892 | 0.84 | PDE5A (0.76) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29832145 | 0.83 | PDE5A (0.91) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL290788 | 0.83 | PDE5A (0.91) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL6068146 | 0.83 | PDE5A (0.67) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29408502 | 0.82 | PDE5A (0.69) | PDE5AMAPTKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114984229-A | Treatment of addiction and impulse control disorders using PDE7 inhibitors | 奥默罗斯公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112168972-A | Treatment of addiction and impulse control disorders using PDE7 inhibitors | 奥默罗斯公司 | 2021-01-05 | — | — | CN | disclosed |